

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--|-----------------|----------------------|-------------------------|------------------|
| 10/009,500 | 12/11/2001 | Maria Kordowicz | MERCK 2332 | 4910 |
| 23599 75 | 7590 02/17/2004 | | EXAMINER | |
| MILLEN, WHITE, ZELANO & BRANIGAN, P.C. | | | PATTERSON, CHARLES L JR | |
| 2200 CLAREN SUITE 1400 | DON BLVD. | | ART UNIT | PAPER NUMBER |
| ARLINGTON, VA 22201 | | | 1652 | |
| | | | DATE MAILED: 02/17/2004 | |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | Application No. | Applicant(s) | | | | |
|---|---|--------------------------|--|--|--|--|
| Office Action Command | 10/009,500 | KORDOWICZ ET AL. | | | | |
| Office Action Summary | Examiner | Art Unit | | | | |
| | Charles L. Patterson, Jr. | 1652 | | | | |
| Th MAILING DATE of this communication appears on the cover she t with the correspondence address Period for Reply | | | | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). | | | | | | |
| Status | | | | | | |
| 1) Responsive to communication(s) filed on | Responsive to communication(s) filed on | | | | | |
| 2a) ☐ This action is FINAL . 2b) ☐ This | This action is FINAL . 2b) ☐ This action is non-final. | | | | | |
| | Since this application is in condition for allowance except for formal matters, prosecution as to the merits is | | | | | |
| closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. | | | | | | |
| Disposition of Claims | | | | | | |
| 4)⊠ Claim(s) <u>1-20</u> is/are pending in the application. | | | | | | |
| 4a) Of the above claim(s) is/are withdrawn from consideration. | | | | | | |
| 5) Claim(s) is/are allowed. | | | | | | |
| | 6) Claim(s) is/are rejected. | | | | | |
| 7) Claim(s) is/are objected to. | | | | | | |
| 8)⊠ Claim(s) <u>1-20</u> are subject to restriction and/or o | election requirement. | | | | | |
| Application Papers | | | | | | |
| 9) ☐ The specification is objected to by the Examiner. | | | | | | |
| 10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. | | | | | | |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). | | | | | | |
| Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. | | | | | | |
| The oath of declaration is objected to by the Ex | taminer. Note the attached Office | Action of form P1O-152. | | | | |
| Priority under 35 U.S.C. § 119 | | | | | | |
| 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document | s have been received. | | | | | |
| 2. Certified copies of the priority documents have been received in Application No | | | | | | |
| 3. Copies of the certified copies of the prior | * | d in this National Stage | | | | |
| application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. | | | | | | |
| | | | | | | |
| Attachment(s) | | | | | | |
| 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date | | | | | | |
| 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | atent Application (PTO-152) | | | | | |
| Paper No(s)/Mail Date 6) Other: | | | | | | |

Application/Control Number: 10/009,500

Art Unit: 1652

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-9, 16-20, drawn to a protein of SEQ ID NO:1, a pharmaceutical composition comprising the protein and the use of the protein as a medicament for the treatment of 4 different conditions.

Group II, claims 10-11, 14-15, drawn to a DNA sequence of SEQ ID NO:2.

Group III, claims 10-11, 14-15, drawn to a DNA sequence of SEQ ID NO:4.

Group IV, claims 10-11, 14-15, drawn to a DNA sequence of SEQ ID NO:6.

Group V, claims 12-13, drawn to a recombinant protein of SEQ ID NO:3.

Group VI, claims 12-13, drawn to a recombinant protein of SEQ ID NO:5.

Group VII, claims 12-13, drawn to a recombinant protein of SEQ ID NO:7.

The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The proteins of Groups I and V-VII are completely different chemical compounds from the DNA sequences of Groups II-IV. Because at least European Patent 0193330, included in the PCT search report, is prior art for the protein, the DNA is not a special technical feature of the protein and is properly restricted from it. The proteins of SEQ ID NO:1, 3, 5 and 7 and the DNA of SEQ ID NO:2, 4 and 6 are different and therefore are properly restricted.

Application/Control Number: 10/009,500

Art Unit: 1652

It is noted that claims 18-19 are generic to any pharmaceutical composition whatsoever. However, for the purposes of this restriction it is placed Group I.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charles L. Patterson, Jr., PhD, whose telephone number is 571-272-0936. The examiner can normally be reached on Monday - Friday from 7:30 to 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-308-4242.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see

Application/Control Number: 10/009,500 Page 4

Art Unit: 1652

http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Charles 1. Patterson, Jr.

Primary Examiner Art Unit 1652

Patterson February 11, 2004